Ultrasound-Guided Needle Aspiration Biopsy of Superficial Metastasis of Lung Cancer with and without Rapid On-Site Evaluation: A Randomized Trial

Vanina Livi 1, Giovanni Sotgiu 2, Alessandra Cancellieri 3, Daniela Paioli 1, Fausto Leoncini 1*, Daniele Magnini 1 and Rocco Trisolini 1,4*

1 Interventional Pulmonology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
2 Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy
3 Pathology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
4 Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy
* Correspondence: rocco.trisolini@policlinicogemelli.it

Simple Summary: Pulmonologist-performed US-NAB of “superficial” metastatic lesions is safe and has an excellent diagnostic yield for both tissue diagnosis and molecular profiling regardless of the use of rapid on-site evaluation. These findings have important implications for costs, hospital resource allocation, and the globally widespread utilization of US-NAB.

Abstract: Background and Objective: Studies which evaluated the role of an ultrasound-guided needle aspiration biopsy (US-NAB) of metastases from lung cancer located in “superficial” organs/tissues are scant, and none of them assessed the possible impact of rapid on-site evaluation (ROSE) on diagnostic accuracy and safety outcomes. Methods: Consecutive patients with suspected superficial metastases from lung cancer were randomized 1:1 to US-NAB without (US-NAB group) or with ROSE (ROSE group). The diagnostic yield for a tissue diagnosis was the primary outcome. Secondary outcomes included the diagnostic yield for cancer genotyping, the diagnostic yield for PD-L1 testing, and safety. Results: During the study period, 136 patients were randomized to receive an US-NAB with (n = 68) or without ROSE (n = 68). We found no significant differences between the ROSE group and the US-NAB group in terms of the diagnostic yields for tissue diagnosis (94.1% vs. 97%, respectively; p = 0.68), cancer genotyping (88% vs. 91.8%, respectively; p = 0.56), and PD-L1 testing (93.5% vs. 90.6%, respectively; p = 0.60). Compared to the diagnostic US-NAB procedures, the non-diagnostic procedures were characterized by less common use of a cutting needle (66.6% vs. 96.9%, respectively; p = 0.0004) and less common retrieval of a tissue core (37.5% vs. 98.5%; p = 0.0001). Only one adverse event (vasovagal syncope) was recorded. Conclusion: US-NAB of superficial metastases is safe and has an excellent diagnostic success regardless of the availability of ROSE. These findings provide a strong rationale for using US-NAB as the first-step method for tissue acquisition whenever a suspected superficial metastatic lesion is identified in patients with suspected lung cancer.

Keywords: lung cancer; bronchoscopy and interventional techniques; pathology; radiology and other imaging

1. Introduction

Personalized oncological treatments have markedly improved the response rate, quality of life, and survival of patients with locally advanced and advanced non-small-cell lung cancer [1–3]. However, despite the availability of highly effective endoscopy-based and CT-based biopsy procedures, 3% to 52% of patients who are potentially eligible for targeted therapies or immunotherapies do not have access to a diagnosis or to thorough
and/or timely molecular profiling for a variety of reasons, including poor performance status, unfavorable tumor location, and poor quality of the biopsy samples [4–8].

Lung cancer metastases located in superficial organs/tissues are ideal targets for an ultrasound-guided needle aspiration biopsy (US-NAB), which is less invasive and costly than both advanced diagnostic bronchoscopy and CT-guided biopsy. In the specific setting of superficial lesions, the role of US-NAB has been assessed in a limited proportion of the patient population in a handful of observational studies [9–11]. Interestingly, the diagnostic yield (54% to 86%) reported in studies in which US-NAB was performed without rapid on-site evaluation (ROSE) [9,10] was lower than that obtained in the only study in which ROSE was systematically used (98%) [11]. While the above results may point to the possible added value of ROSE, data obtained in other clinical settings suggest caution. In particular, several randomized controlled trials assessing the value of ROSE performed on specimens retrieved endoscopically from lymphadenopathy [12–15] have failed to confirm the increase in diagnostic yield associated with its use that had previously been suggested by observational studies [16–18].

The aim of the present randomized study is to assess the impact of ROSE on diagnostic accuracy and potential complications in consecutive patients with suspected lung cancer showing a possible superficial metastatic lesion on imaging studies (CT and/or PET).

2. Methods

2.1. Study Design, Setting, and Participants

This randomized controlled trial was approved by the Ethics Committee of the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Prot. ID 3866) and was registered at ClinicalTrial.gov (NCT04618874).

Individuals were eligible if they were >18 years old, had a suspected superficial metastasis from lung cancer on CT and/or PET, and had an indication for tissue acquisition. The key exclusion criteria were as follows: unwillingness or inability to consent; evidence of a non-correctable coagulation disorder; and use of antiplatelet (excluding aspirin) or anticoagulant drugs that could not be discontinued.

2.2. Randomization and Interventions

Consecutive patients were randomized 1:1 to US-NAB without (US-NAB group, standard care) or with ROSE (ROSE group, intervention). The randomization sequence was computer-generated and we placed the assignments in opaque, sealed envelopes. Owing to the nature of the interventions, the participants and the investigators could not be blinded to the group allocation. The recruitment took place between 1 April 2021 and 31 March 2022.

All study procedures were carried out by a team of 5 interventional pulmonologists. Each patient underwent an ultrasound examination using an Hitachi Aloka Arietta 850 ultrasound platform (Steinhausen, Switzerland), and the “target” lesion was evaluated with both a convex and a linear probe. In cases in which sampling was considered feasible and safe (i.e., lack of interposition of large vessels), the skin was sterilized and 2–5 mL of 2% lidocaine was injected into the subcutaneous area of interest. Then, the lesion was sampled using a “freehand” technique with a 22-gauge needle Farmatexa Softouch syringe (Farmac-Zabban, Calderara Di Reno, Bologna, Italy).

In the US-NAB arm, the specimen obtained with the first needle pass was smeared on 2–4 glass slides, which were placed into a 96% alcohol solution and were later stained with the Papanicolaou method in the Pathology lab. Then, 2 to 4 more needle passes were performed, at the discretion of the operator, depending on the size of the lesion, the needle type used, and the gross appearance of the material retrieved. After the first needle pass, an 18G or 16G cutting needle (Biomol biopsy set, Hospital Service SPA, Rome, Italy) was used, whenever considered possible and safe.

In the ROSE arm, the specimen obtained with the first needle pass was smeared on 2–4 glass slides. One slide was air-dried, stained with Diff-Quik, and submitted to ROSE,
whereas the remaining were put into an ethanol solution and sent to the Pathology lab. Further sampling was guided by the ROSE results. If successful sampling (i.e., representativeness of the lesion’s tissue or clues to a specific pathologic diagnosis) was confirmed, 2 to 4 more needle passes were performed, depending on the size of the lesion and the gross appearance of the material retrieved, using a cutting needle whenever considered possible and safe.

In patients with more than one superficial lesion, the decision to sample one or more lesions was left at the discretion of the operator, who could decide based on the ROSE findings (ROSE arm) or on the gross examination of the biopsy material (US-NAB arm).

After the procedure, each patient was monitored in the recovery room for at least 1 h before being discharged (outpatients) or sent back to their hospital ward (inpatients).

Molecular profiling included testing for PD-L1 and for the genes reimbursed at the time of biopsy by the Italian Healthcare System (i.e., EGFR, ALK, ROS1, KRAS, and BRAF). A minimum of 30 ng/L of DNA and 15 ng/L of RNA were deemed sufficient to carry out the above analysis.

2.3. Outcomes

The primary outcome was the diagnostic yield of the US-NAB. Secondary outcomes were the following: (a) the diagnostic yield for cancer genotyping (successful completion of EGFR, KRAS, ALK, ROS1, and BRAF testing); (b) the diagnostic yield for PD-L1 testing; and (c) safety (percentage of adverse events).

2.4. Sample Size Calculation and Statistical Analysis

Based on the limited data from the observational studies available in the literature [9–11], the diagnostic yield of US-NAB with ROSE [11] was expected to be higher than that of US-NAB without ROSE [9,10] by 20% (90% vs. 70%). Considering a type I error $\alpha$ of 5%, a power $1 - \beta$ of 80%, and a drop-out rate of 10%, a sample size of 136 patients was estimated.

Qualitative variables were described with absolute and relative (percentage) frequencies, whereas quantitative variables were described with means (standard deviations) or medians (interquartile ranges), depending on their normal or non-normal distribution. Statistical differences between qualitative variables were evaluated using chi-squared or Fisher’s exact test, as appropriate. Student’s $t$-test and Mann–Whitney test were performed to assess statistically significant differences for normally and non-normally distributed quantitative variables, respectively. A two-tailed $p$-value less than 0.05 was considered statistically significant. Data were analyzed using STATA, version 16 (StatsCorp, College Station, TX, USA).

3. Results

Between 1 April 2021 and 31 March 2022, 144 patients were screened and 136 were enrolled in the study (Figure 1). Table 1, which displays the baseline characteristics of the patients and the procedures, shows no significant differences in demographics and clinical characteristics. One hundred forty-four lesions belonging to several superficial anatomical areas were sampled (Figures 2 and 3), but superficial lymph nodes (103, 71.5%) and bone metastases (18, 12.5%) were the most frequent targets. The final diagnosis was metastasis from a pulmonary tumour in the majority of patients (121, 89%), with adenocarcinoma (90, 66.2%) and small-cell lung cancer (15, 11%) being the most prevalent histologic subtypes.
and bone metastases (18, 12.5%) were the most frequent targets. The final diagnosis was metastasis from a pulmonary tumour in the majority of patients (121, 89%), with adenocarcinoma (90, 66.2%) and small-cell lung cancer (15, 11%) being the most prevalent histologic subtypes.

**Figure 1.** Consort flow diagram of the study.

**Table 1.** Demographics and baseline characteristics of the patients (136) and lesions (144).

|                      | ROSE Group US-NAB Group |
|----------------------|-------------------------|
| Mean (SD) age, years | 67.6 (10.3) 67.3 (8.5)  |
| Gender, n. (%)       | Female 30 (44) 28 (41)  |
|                      | Male 38 (56) 40 (59)    |
| Smoking history, n. (%) | Current 19 (30) 21 (31) |
|                      | Former 35 (51.5) 36 (53) |
|                      | Never 14 (20.5) 11 (16) |
| Lesions sampled, n.  | 72 72                   |
| Median (IQR) lesion size, mm | Short axis 13.2 (9.2–18.3) 12.4 (9–16.1) |
|                      | Long axis 18.2 (12.4–25.1) 16.5 (12.8–26.6) |
| Metastatic site, n. (%) | Lymph node 54 (75) 49 (68) |
|                      | Supraclavicular 44 40 |
|                      | Cervical 8 7 |
|                      | Axillary 2 1 |
|                      | Mammary 0 1 |
|                      | Bone 7 (9.7) 11 (15.3) |
| Subcutaneous tissue  | 6 (8.3) 6 (8.3) |
| Thoracic wall        | 3 (4.2) 3 (4.2) |
| Muscle               | 2 (2.8) 1 (1.4) |
| Pleura               | 0 (0) 2 (2.8) |
| Needle gauge, n. (%) | 22G 4 (5.9) 2 (3) |
|                      | 22G + 18G 53 (77.9) 60 (88.2) |
|                      | 22G + 16G 11 (16.2) 6 (8.8) |
| Tissue core retrieval, n. (%) | 64 (94.1) 66 (97) |
| Final diagnosis per patient, n. (%) | Adenocarcinoma 41 (60.3) 49 (72) |
|                      | Squamous cell carcinoma 4 (5.9) 1 (1.5) |
|                      | Small-cell lung cancer 11 (16) 4 (5.9) |
|                      | Large cell neuroendocrine carcinoma 1 (1.5) 0 (0) |
|                      | Carcinoid tumor 1 (1.5) 1 (1.5) |
|                      | NSCLC NOS 4 (5.9) 4 (5.9) |
|                      | Metastasis from extrapulmonary tumor 3 (4.5) 5 (7.4) |
|                      | Lymphoproliferative disorder 2 (2.9) 2 (2.9) |
|                      | Tuberculosis 0 (0) 2 (2.9) |
|                      | Reactive lymphadenopathy 1 (1.5) 0 (0) |

**Figure 2.** Contrast-enhanced CT (A) and corresponding US-NAB image (B) showing a large thoracic wall lesion (red arrow) adjacent to the liver, which contains multiple nodular lesions consistent with metastases; contrast-enhanced CT (C) and corresponding US-NAB image (D) showing a subcentimetric subcutaneous nodule (red arrow) in the anterior aspect of the right hemithorax; and contrast-enhanced CT (E) and corresponding US-NAB image (F) from an enlarged, round cervical lymph node (red arrow).
Table 1. Demographics and baseline characteristics of the patients (136) and lesions (144).

|                          | ROSE Group            | US-NAB Group          |
|--------------------------|-----------------------|-----------------------|
| **Mean (SD) age, years** | 67.6 (10.3)           | 67.3 (8.5)            |
| **Gender, n. (%)**       |                       |                       |
| Female                   | 30 (44)               | 28 (41)               |
| Male                     | 38 (56)               | 40 (59)               |
| **Smoking history, n. (%)** |                     |                       |
| Current                  | 19 (30)               | 21 (31)               |
| Former                   | 35 (51.5)             | 36 (53)               |
| Never                    | 14 (20.5)             | 11 (16)               |
| **Lesions sampled, n.**  |                       |                       |
| Short axis               | 72                    | 72                    |
| Median (IQR) lesion size, mm |                 |                       |
| Short axis               | 13.2 (9.2–18.3)       | 12.4 (9–16.1)         |
| Long axis                | 18.2 (12.4–25.1)      | 16.5 (12.8–26.6)      |
| **Metastatic site, n. (%)** |                     |                       |
| Lymph node               | 54 (75)               | 49 (68)               |
| Supraclavicular          | 44                    | 40                    |
| Cervical                 | 8                     | 7                     |
| Axillary                 | 2                     | 1                     |
| Mammary                  | 0                     | 1                     |
| Bone                     | 7 (9.7)               | 11 (15.3)             |
| **Subcutaneous tissue**  |                       |                       |
| Thoracic wall            | 6 (8.3)               | 6 (8.3)               |
| Muscle                   | 3 (4.2)               | 3 (4.2)               |
| Pleura                   | 2 (2.8)               | 1 (1.4)               |
|                          | 0 (0)                 | 2 (2.8)               |
| **Needle gauge, n. (%)** |                       |                       |
| 22G                      | 4 (5.9)               | 2 (3)                 |
| 22G + 16G                | 53 (77.9)             | 60 (88.2)             |
| 22G + 16G                | 11 (16.2)             | 6 (8.8)               |
| **Tissue core retrieval, n. (%)** |                 |                       |
|                          | 64 (94.1)             | 66 (97)               |
| **Final diagnosis per patient, n. (%)** |                 |                       |
| Adenocarcinoma           | 41 (60.3)             | 49 (72)               |
| Squamous cell carcinoma  | 4 (5.9)               | 1 (1.5)               |
| Small-cell lung cancer   | 11 (16)               | 4 (5.9)               |
| Large cell neuroendocrine carcinoma | 1 (1.5) | 0 (0) |
| Carcinoid tumor          | 1 (1.5)               | 1 (1.5)               |
| NSCLC NOS                | 4 (5.9)               | 4 (5.9)               |
| Metastasis from extrapulmonary tumor | 3 (4.5) | 5 (7.4) |
| Lymphoproliferative disorder | 2 (2.9) | 2 (2.9) |
| Tuberculosis             | 0 (0)                 | 2 (2.9)               |
| Reactive lymphadenopathy  | 1 (1.5)               | 0 (0)                 |

Table 2 shows the results of the study endpoints. We found no significant differences between the ROSE group and the US-NAB group in terms of the diagnostic yield for tissue diagnosis (94.1% vs. 97%, respectively; $p = 0.68$). Subgroup analyses did not show any significant differences in the diagnostic yield according to the location of the target lesion or to the final histologic diagnosis.

The diagnostic yields for both cancer genotyping and PDL1 testing, which were requested by the treating oncologist in 91 and 99 patients, respectively, were excellent in both study groups, with no statistically significant differences (Table 2).
Table 2 shows the results of the study endpoints. We found no significant differences between the ROSE group and the US-NAB group in terms of the diagnostic yield for tissue diagnosis (94.1% vs. 97%, respectively; \(p = 0.68\)). Subgroup analyses did not show any significant differences in the diagnostic yield according to the location of the target lesion or to the final histologic diagnosis.

Table 2. Study outcomes.

| Outcomes                          | ROSE Group (No. 68) | US-NAB Group (No. 68) | \(p\)-Value |
|-----------------------------------|---------------------|-----------------------|-------------|
| **Primary outcome**               |                     |                       |             |
| Diagnostic yield for tissue diagnosis | 64/68 (94.1%)      | 66/68 (97%)           | 0.68        |
| **Secondary outcome**             |                     |                       |             |
| Diagnostic yield for cancer genotyping * | 37/42 (88%)       | 45/49 (91.8%)         | 0.56        |
| Diagnostic yield for PD-L1 testing * | 43/46 (93.5%)     | 48/53 (90.6%)         | 0.60        |
| Complications                     | 1/68 (1.5%)         | 0/68 (0.0%)           | 1.00        |

* Molecular profiling results are given for patients in whom genotyping and/or PDL1 testing were requested by the medical oncologist (see Section 3).

Table 3 shows the main demographic, clinical, and procedural characteristics of the six patients in whom the US-NAB procedure was non-diagnostic. Comparing patients with a diagnostic and a non-diagnostic US-NAB procedure, we found a statistically significant difference in regard to the following two technical characteristics. A cutting needle (16G or 18G) was used more frequently in patients with a diagnostic procedure than in those with a non-diagnostic US-NAB procedure (126/130, 96.9% vs. 4/6, 66.6%; \(p = 0.0004\)). A tissue core was obtained more frequently from the 136 lesions sampled in the 130 patients with a diagnostic US-NAB than from the eight lesions sampled in the six patients with a non-diagnostic procedure (134/136, 98.5% vs. 3/8, 37.5%; \(p = 0.0001\)).

A single adverse event (vasovagal syncope) was observed during the study.
Table 3. Demographic, clinical, and procedural characteristics in the six patients with a non-diagnostic US-NAB.

| Study Group | Age/Sex | Lesion Location | No. Lesions Sampled | Needle Used | Tissue Core Retrieved | Final Diagnosis       |
|-------------|---------|----------------|---------------------|-------------|----------------------|-----------------------|
| #1 ROSE     | 77/M    | LN             | 1                   | 18G         | No                   | NSCLC NOS             |
| #2 ROSE     | 73/M    | LN             | 1                   | 22G         | No                   | SQCC                  |
| #3 ROSE     | 66/F    | LN             | 2                   | 18G         | Yes                  | Adenocarcinoma        |
| #4 ROSE     | 48/M    | LN             | 2                   | 22G         | No                   | Adenocarcinoma        |
| #5 US-NAB   | 66/F    | LN             | 1                   | 18G         | Yes                  | Adenocarcinoma        |
| #6 US-NAB   | 86/M    | Bone           | 1                   | 18G         | Yes                  | Adenocarcinoma        |

Abbreviations: LN = lymph node; NSCLC NOS = non-small cell lung cancer not otherwise specifiable; SQCC = squamous cell carcinoma.

4. Discussion

The present study found that US-NAB of superficial metastases from lung cancer has high diagnostic success and safety regardless of the availability of ROSE. These findings, which confirm the importance using randomized trials to verify the hypothesis raised by observational studies, have important potential implications for costs, allocation of healthcare resources, and the widespread utilization of US-NAB sampling for this specific indication.

The diagnostic yields for tissue diagnosis and molecular profiling that we achieved are at least similar to those reported for advanced endoscopy-based and CT-based biopsy methods [19–23] but with a much better safety profile [23–26]. No currently available studies aiming at assessing the role of US-NAB for the diagnosis of superficial metastases reported clinically important complications [9–11]. This is not surprising, as US-NAB is performed following a sterile protocol, under real-time ultrasound control, and after an evaluation of the availability of a safe, vessel-free path to the lesion. Furthermore, sampling a superficial metastatic target significantly reduces the risk of a pneumothorax.

Besides its high success rate and safety regardless of the use of on-site cytologic review, US-NAB of a superficial lesion is associated with several other potential organizational, economic, and ethical advantages. It does not require sedation, does not expose patients and health care staff to radiation, can be performed safely in patients with poor performance status, and is less invasive and costly than endoscopic or CT-guided procedures [27–29]. Furthermore, respiratory physicians, who are frequently involved in the diagnostic and staging pathway of lung cancer patients, may rapidly schedule and perform an US-NAB when indicated, and may decide for more invasive procedures when the US-NAB is inconclusive [30]. However, there is a relative lack of knowledge of these potential advantages among the stakeholders involved in the lung cancer pathway, and US-NAB is not even mentioned among the diagnostic methods for diagnosing or staging NSCLC by most international oncological and thoracic scientific societies [31–33]. This is confirmed by the fact that most of the patients that we enrolled in the present study were referred to our division for bronchoscopy and underwent an US-NAB instead after we carefully reviewed their imaging studies and identified a suspected superficial metastasis.

Besides lymph nodes, bone lesions were the most common targets in our study. Remarkably, we observed the presence of metastatic lesions completely replacing the bone structure in a non-negligible percentage of patients with advanced lung cancer. In most such cases, the needle found no resistance in penetrating the lesion and the histological examination of the biopsy specimen showed almost no residual bone tissue. In the few cases in which we had to biopsy a metastatic lesion within a partially intact bone, we agreed with the pathology department that the specimen did not undergo decalcification. The latter, in fact, is known to cause the denaturation of the nucleic acids and may compromise the accomplishment of a reliable cancer genotyping [34].

Although the small number of non-diagnostic procedures weakens the strength of the comparison with diagnostic US-NABs, the use of a cutting needle (16G or 18G) and the retrieval of tissue cores were significantly more common in the diagnostic cases. This is
not surprising as tissue cores allow the pathologist to assess the tissue architecture and can make it easier to diagnose with confidence those conditions which may only be suspected on cytological grounds.

The randomized design and the variety of superficial lesions that were sampled represent the strengths of our study. However, some limitations that possibly affect the study’s external validity should be acknowledged. ROSE was performed by a pathologist (A.C.) with extensive experience in pulmonary pathology and on-site cytologic review in both clinical and research settings [12,35–37]. Furthermore, more than 200 US-NABs from superficial lesions are carried out annually in our center by experienced operators. The higher percentage of patients in whom a cutting needle was used in this study, in comparison to that of an observational study [11] we performed only a few years ago in the same clinical setting (95.6% vs. 71%, respectively), suggests a higher level of confidence of the operators in the management of superficial lesions of any size.

5. Conclusions

In conclusion, our results highlight the importance of carefully reviewing the imaging of patients with suspected lung cancer who undergo evaluation for a biopsy, and the importance of using US-NAB as the first-step method whenever a suspected superficial metastatic lesion is identified.

Author Contributions: R.T. contributed to conceptualization, methodology, investigation, and writing—original draft preparation. G.S. contributed to conceptualization, methodology, formal analysis, and writing—review and editing. V.L. contributed to conceptualization, investigation, resources, and writing—review and editing. A.C., D.P., D.M. and F.L. contributed to investigation, resources, and writing—review and editing. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: This study was performed in accordance with the Declaration of Helsinki and was approved by the Medical Ethical Committee of the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Prot. ID 3866, date of approval 11 March 2021). All participants provided written informed consent to participate in this study (Clinical trial registration: NCT 04618874 at ClinicalTrials.gov).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data can be shared upon request.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Shah, D.R.; Masters, G.A. Precision medicine in lung cancer treatment. *Surg. Oncol. Clin.* 2020, 29, 15–21. [CrossRef]
2. Antonia, S.J.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Kurata, T.; Chiappori, A.; Lee, K.H.; De Wit, M.; et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. *N. Engl. J. Med.* 2018, 379, 2342–2350. [CrossRef]
3. Forde, P.M.; Spicer, J.; Lu, S.; Provencio, M.; Mitsudomi, T.; Awad, M.M.; Felip, E.; Broderick, S.R.; Brahmer, J.R.; Swanson, S.J.; et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. *N. Engl. J. Med.* 2022. [CrossRef] [PubMed]
4. Smeltzer, M.P.; Wynes, M.W.; Lantuejoul, S.; Soo, R.; Ramalingam, S.S.; Varella-Garcia, M.; Taylor, M.M.; Richeimer, K.; Wood, K.; Howell, K.E.; et al. The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. *J. Thorac. Oncol.* 2020, 15, 1434–1448. [CrossRef]
5. Ahn, M.-J. Molecular testing in lung cancer: Still big gap in implementation for real-world use. *J. Thorac. Oncol.* 2020, 15, 1399–1400. [CrossRef]
6. Rolfo, C.; Mack, P.C.; Scagliotti, G.V.; Baas, P.; Barlesi, F.; Bivona, T.G.; Herbst, R.S.; Mok, T.S.; Peled, N.; Pirker, R.; et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): A statement paper from the IASLC. *J. Thorac. Oncol.* 2018, 13, 1248–1268. [CrossRef] [PubMed]
7. Gondos, A.; Paz-Ares, L.G.; Saldana, D.; Thomas, M.; Mascaux, C.; Bubendorf, L.; Barlesi, F. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study. *Lung Cancer* 2022, 167, 41–48. [CrossRef]
8. Hess, K.M.; Krein, P.M.; Haldane, D.; Han, Y.; Sireci, A.N. Biomarker testing for patients with advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) in the USA, 2015-2021. *JTO Clin. Res. Rep.* 2022, 3, 100336.

9. Stigt, J.A.; Oostdijk, A.d.H.; Boers, J.E.; van den Berg, J.W.K.; Groen, H.J.M. Percutaneous ultrasound-guided biopsies in the evaluation of thoracic tumors after PET-CT: A prospective diagnostic study. *Respiration* 2012, 83, 45–52. [CrossRef]

10. Laursen, C.B.; Naur, T.M.; Bodtger, U.; Colella, S.; Naqibullah, M.; Minddal, V.; Konge, L.; Davidsen, J.R.; Hansen, N.C.; Graumann, O.; et al. Ultrasound-guided lung biopsy in the hands of respiratory physicians. Diagnostic yield and complications in 215 consecutive patients in 3 centers. *J. Bronchol. Intervent. Pulmonol.* 2016, 23, 220–228. [CrossRef] [PubMed]

11. Livi, V.; Païoli, D.; Cancelleri, A.; Bettì, S.; Natali, F.; Ferrari, M.; Fiorentino, M.; Trisolini, R. Diagnosis and molecular profiling of lung cancer by percutaneous ultrasound-guided biopsy of superficial metastatic sites is safe and highly effective. *Respiration* 2021, 100, 515–522. [CrossRef] [PubMed]

12. Trisolini, R.; Cancelleri, A.; Tinelli, C.; Païoli, D.; Scudeller, L.; Casadei, G.P.; Parri, S.F.; Livi, V.; Bondì, A.; Boaròn, M.; et al. Rapid on-site evaluation of transbronchial aspirates for the diagnosis of hilar and mediastinal adenopathy. A randomized trial. *CHEST* 2011, 139, 395–401. [CrossRef]

13. Yarmus, L.; Van der Kloot, T.; Lechtzin, N.; Napier, M.; Dressel, D.; Feller-Kopman, D. A randomized prospective trial of the utility of rapid on-site evaluation of transbronchial needle aspirate specimens. *J. Bronchol. Intervent. Pulmonol.* 2011, 18, 121–127. [CrossRef]

14. Oki, M.; Saka, H.; Kitagawa, C.; Kogure, Y.; Murata, N.; Adachi, T.; Ando, M. Rapid on-site cytologic evaluation during endobronchial ultrasound-guided transbronchial needle aspiration for diagnosing of lung cancer: A randomized trial. *Respiration* 2013, 86, 486–492. [CrossRef]

15. Kappelle, W.F.W.; Van Leerdam, M.E.; Schwartz, M.P.; Bülbül, M.; Buikhuisen, W.A.; Brink, M.A.; Sie-Go, D.M.D.S.; Pullens, H.J.M.; Nikolakopoulos, S.; Van Diest, P.J.; et al. Rapid on-site evaluation during endoscopic ultrasound-guided fine-needle aspiration of lymph nodes does not increase diagnostic yield: A randomized multicenter trial. *Am. J. Gastroenterol.* 2018, 113, 677–685. [CrossRef]

16. Davenport, R.D. Rapid on-site evaluation of transbronchial aspirates. *CHEST* 1990, 98, 59–61. [CrossRef]

17. Diette, G.B.; White, P.; Terry, P.; Jenckes, M.; Rosenthal, D.; Rubin, H.R. Utility of rapid on-site cytopathology assessment for bronchoscopic evaluation of lung masses and adenopathy. *CHEST* 2000, 117, 1186–1190. [CrossRef]

18. Chin R, McCain TW, Lucia MA, Cappellari JO, Adair NE, Lovato JF; et al. Diagnostic yield and complications for bronchoscopy for peripheral lung lesions. *Respiration* 2014, 87, 139–149. [CrossRef]

19. Kramer, T.; Annema, J.T. Advanced bronchoscopic techniques for the diagnosis and treatment of peripheral lung lesions. *Lung Cancer* 2021, 161, 152–162. [CrossRef]

20. Dhoooria, S.; Aggarwal, A.N.; Gupta, D.; Behera, D.; Agarwal, R. Utility and safety of ultrasound with bronchoscope-guided fine-needle aspiration in mediastinal lymph node sampling: Systematic review and meta-analysis. *Respir. Care* 2015, 60, 1040–1050. [CrossRef]

21. Takeshita, J.; Masago, K.; Kato, R.; Hata, A.; Kaji, R.; Fujita, S.; Katakami, N. CT-guided fine needle aspiration and core needle biopsies of pulmonary lesions: A single center experience with 750 biopsies in Japan. *Am. J. Roentgenol.* 2015, 204, 29–34. [CrossRef]

22. Asano, F.; Aoe, M.; Ohsaki, Y.; Okada, Y.; Sasada, S.; Sato, S.; Suzuki, E.; Semba, H.; Fukuoka, K.; Fujino, S.; et al. Complications associated with endobronchial ultrasound-guided transbronchial needle aspiration: A nationwide survey by the Japan Society for Respiratory Endoscopy. *Respir. Res.* 2013, 14, 50. [CrossRef]

23. Folich, E.E.; Pritchett, M.A.; Neal, M.A.; Bowling, M.R.; Murgu, S.D.; Krimsky, W.S.; Murillo, B.A.; LeMense, G.P.; Minnich, D.; Bansal, S.; et al. Electromagnetic navigation bronchoscopy for peripheral pulmonary lesions: One-year results of the prospective, multicenter NAVIGATE study. *J. Thorac. Oncol.* 2019, 14, 445–458. [CrossRef]

24. Ost, D.E.; Ernst, A.; Lei, X.; Kovitz, K.L.; Benzaken, S.; Diaz-Mendoza, J.; Greenhill, S.; Toth, J.; Feller-Kopman, D.; Puchalski, J.; et al. Diagnostic yield and complications for bronchoscopy-guided fine needle aspiration for peripheral lung lesions. *Am. J. Respir. Crit. Care Med.* 2016, 193, 68–77. [CrossRef]

25. Najaì, A.; Al Ahmar, M.; Bonnet, B.; Delpla, A.; Kobe, A.; Madani, K.; Roux, C.; Deschamps, F.; de Baire, T.; Tselikas, L. The PEARL approach for CT-guided lung biopsy: Assessment of complication rates. *Radiology* 2022, 302, 473–480. [CrossRef]

26. Heerink, W.J.; de Bock, G.H.; de Jonge, G.J.; Groen, H.J.M.; Vliegenthart, R.; Oudkerk, M. Complication rates of CT-guided transthoracic lung biopsy: Meta-analysis. *Eur. Radiol.* 2017, 27, 138–148. [CrossRef]

27. Koegelenburg, C.F.N.; von Groote-Bidlingmaier, F.; Bolliger, A. Transthoracic ultrasoundography for the respiratory physician. *Respiration* 2012, 84, 337–350. [CrossRef]

28. Stigt, J.A.; Groen, H.J.M. Percutaneous ultrasonography as imaging modality and sampling guide for Pulmonologists. *Respiration* 2014, 87, 441–451. [CrossRef]

29. Diacon, A.H.; Shuurnans, N.N.; Theron, J.; Shuubert, P.T.; Wright, C.A.; Bolliger, C.T. Safety and yield of ultrasound-assisted transthoracic biopsy performed by pulmonologists. *Respiration* 2004, 71, 519–522. [CrossRef]

30. Ahmed, M.; Daneshvar, C.; Breen, D. Routine neck ultrasound by respiratory physicians in the diagnosis and staging of patients with lung cancer and mediastinal lymphadenopathy: A prospective pilot study. *ERJ Open Res.* 2020, 6, 00180–02019. [CrossRef]
31. Planchard, D.; Popat, S.T.; Kerr, K.; Novello, S.; Smit, E.F.; Faivre-Finn, C.; Mok, T.S.; Reck, M.; Van Schil, P.E.; Hellmann, M.D.; et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* 2018, 29, iv192–iv237. [CrossRef] [PubMed]

32. Rivera, M.P.; Mehta, A.C.; Wahidi, M.M. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013, 143, e142S–e165S. [CrossRef] [PubMed]

33. Passiglia, F.; Pilotto, S.; Facchinetti, F.; Bertolaccini, L.; Del Re, M.; Ferrara, R.; Franchina, T.; Malapelle, U.; Menis, J.; Passaro, A.; et al. Treatment of advanced non-small cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. *Crit. Rev. Oncol. Hematol.* 2019, 146, 102858. [CrossRef]

34. Singh, V.M.; Salunga, R.C.; Huang, V.J.; Tran, Y.; Erlander, M.; Plumlee, P.; Peterson, M.R. Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. *Ann. Diagn. Pathol.* 2013, 17, 322–326. [CrossRef]

35. Trisolini, R.; Cancellieri, A.; Tinelli, C.; De Biase, D.; Valentini, I.; Casadei, G.; Paioli, D.; Ferrari, F.; Gordini, G.; Patelli, M.; et al. Randomized trial of endobronchial ultrasound-guided transbronchial needle aspiration with and without rapid on-site evaluation for lung cancer genotyping. *CHEST* 2015, 148, 1430–1437. [CrossRef]

36. Natali, F.; Cancellieri, A.; Tinelli, C.; De Silvestri, A.; Livi, V.; Ferrari, M.; Romagnoli, M.; Paioli, D.; Trisolini, R. A trained pulmonologist may reliably assess endosonography-derived lymph node samples during rapid on-site evaluation. *Respiration* 2019, 97, 540–547. [CrossRef]

37. Natali, F.; Cancellieri, A.; Giunchi, F.; De Silvestri, A.; Livi, V.; Ferrari, M.; Paioli, D.; Betti, S.; Fiorentino, M.; Trisolini, R. Interobserver agreement between pathologist, pulmonologist and molecular pathologist to estimate the tumor burden in rose smears from endosonography and guided-bronchoscopy. *Cytopathology* 2020, 31, 303–309. [CrossRef]